Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
Principal Investigator
Ronald Chen, MD MPH
Status
Closed to Accrual & Treatment
Date Opened To Accrual
March 27 2019
Disease Site
Cancer Care Delivery Research [CD]
Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine if the experimental arm (increased doses of SCP) has more patients who saw a primary care provider and had blood glucose and cholesterol checked in Year 2 (13-24 months) after finishing RT as compared to the control arm.
Patient Population
The participant must have a diagnosis of prostate adenocarcinoma that will be treated with RT plus ADT with curative intent. Both definitive RT (intact prostate) and post-prostatectomy RT patients are eligible.
Target Accrual
544
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.